Send to

Choose Destination
Exp Clin Endocrinol Diabetes. 2017 May;125(5):322-326. doi: 10.1055/s-0043-104532. Epub 2017 Mar 16.

Serum Fibroblast Growth Factor 1 is Associated with the Decreased Risk of Obesity in Human.

Author information

School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Department of Geriatrics, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Department of Cardiology, Zhejiang Hospital, Hangzhou, Zhejiang, China.
The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Department of Gastroenterology, The Affiliated Hospital, Xuzhou Medical University, Xuzhou, Jiangsu, China.


As a transducer of PPARγ signaling, recent evidence supports that fibroblast growth factor 1 (FGF1) mediates adipose tissue remodeling and insulin sensitivity. This study is to assess the role of serum FGF1 in obesity. A hospital-based case-control study of 154 subjects was conducted. Serum level of FGF1 was measured by enzyme-linked immunosorbent assay. The serum level of FGF1 in the lean (119.0 [103.1-146.1] pg/ml) was higher than it in the subjects with overweight/obesity (111.9 [80.3-127.4] pg/ml, P=0.009). Binary logistic regression models found a reverse association between serum FGF1 level and the risk of overweight/obesity (adjusted odds ratio=0.990, 95% confidence interval [0.981-0.998], P=0.019). Furthermore, serum FGF1 reversely correlated with body mass index (r=-0.176, P=0.029), systolic blood pressure (r=-0.224, P=0.005), diastolic blood pressure (r=-0.185, P=0.022) and triglycerides (r=-0.162, P=0.044). Multiple stepwise linear regression analysis found serum level of FGF1 was dependent on anti-diabetic drugs, hemoglobin A1C, body mass index and sex. Serum level of FGF1 is associated with the decreased risk of obesity in human.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center